Circadian and power spectral changes of RR and QT intervals during treatment of patients with angina pectoris with nadolol providing evidence for differential autonomic modulation of heart rate and ventricular repolarization.
This study evaluates the effects of autonomic manipulation by chronic beta blockade with nadolol on the circadian and power spectral changes of heart rate and QT interval. It was hypothesized that differential innervation of the atria and ventricles by sympathetic and parasympathetic fibers may produce differential effects on heart rate and QT interval variabilities. Holter recordings of 12 male patients (age 63 +/- 7 years) with stable angina were analyzed before and after 3 weeks of nadolol therapy. The QT intervals were individually normalized by an exponential formula to study the circadian variation of QTc. Power spectra of RR and uncorrected QT intervals were obtained by fast-Fourier analysis from 256 consecutive sinus beats during the day at maximal heart rate and during the night at minimal heart rate. Frequency-specific variability was determined from areas under the spectral plots. Both heart rate and QTc exhibited significant circadian patterns (p < 0.01) in opposite phase with each other. Mean heart rate was significantly reduced with nadolol (81 +/- 12 vs 67 +/- 12 beats/min, p < 0.001), with greater reduction during daytime. The mean QTc was unexpectedly reduced after nadolol treatment, with borderline significance (p = 0.06). The RR variability in the frequency range of 0.05 to 0.25 Hz was significantly increased with nadolol at 3:00 A.M. (p < 0.01) but not at 1:00 P.M. The QT variability in the same frequency range of was not significantly increased with nadolol. The power spectra of RR and QT intervals were dissimilar except at the lower frequencies around 0.05 Hz.(ABSTRACT TRUNCATED AT 250 WORDS)
Sarma
J S
JS
City of Hope National Medical Center, Duarte, California 91010.
Singh
N
N
Schoenbaum
M P
MP
Venkataraman
K
K
Singh
B N
BN
D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D001341:Autonomic Nervous System / Q000187:drug effects* / Q000503:physiopathology; D002940:Circadian Rhythm / Q000187:drug effects*; D004562:Electrocardiography / Q000187:drug effects*; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005583:Fourier Analysis; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D009248:Nadolol / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D012815:Signal Processing, Computer-Assisted; D014630:Vagus Nerve / Q000187:drug effects / Q000502:physiology; D016276:Ventricular Function / Q000187:drug effects* / Q000502:physiology
D009248:Nadolol